天津中医药2018，Vol.35Issue(3)：195-199,5.DOI:10.11656/j.issn.1672-1519.2018.03.11
保妇康栓治疗宫颈高危型人乳头瘤病毒感染性疾病有效性和安全性系统评价
The efficacy and safety of Baofukang suppository for cervical high risk human papillomavirus(HR-HPV)infection:systematic review
摘要
Abstract
[Objective] To evaluate the efficacy and safety of Baofukang suppository in the treatment of high risk human cervical papillomavirus (HR-HPV). [Methods] The computer searches the Chinese knowledge database, the Wanfang database, the Weipu database,the SinoMed database,the PubMed database and the Cochrane database and the retrieval period is from the construction site to the March 2017.All randomized controlled trials(RCTs)of Baofukang treatment(HR-HPV)were collected.Two reviewers independently screened and extracted the data. The quality of the study methodology was evaluated using the Cochrane System Evaluation Manual Method,the dispute resolved through discussion. [Results]Thirteen RCTs were screened according to the inclusion criteria,and 1 424 patients were included in this study.Meta analysis showed that the Baofukang on the cervical HR-HPV negative rate,compared with the blank control(RR=2.90,95%CI[1.92,4.36])(P<0.000 01),Baofukang and Western medicine Compare with Western medicine(RR=1.39,95%CI[1.23,1.57],P<0.000 01);on effective rate,Baofukang compare with Western medicine(RR=1.36,95%CI[1.11,1.66],P=0.003),Baofukang and Western medicine compare with Western medicine(RR=1.35,95%CI[1.16,1.57],P=0.000 1),the indicators are better than Western medicine; 2 cases of adverse events were reported in the group of Baofukang group (4 cases of adverse events reported in the control group).[Conclusion]The data analysis suggested that Baofukang was effective in the treatment of high risk human papillomavirus. Due to the relatively small number of research samples, the quality of the literature methodology is relatively low, the level of evidence has yet to be improved.关键词
保妇康栓/宫颈高危型人乳头瘤病毒/系统评价/安全性/有效性Key words
Baofukang suppository/cervical high risk human papillomavirus/systematic review/efficacy/safety分类
医药卫生引用本文复制引用
季昭臣,杨丰文,张立双,张明妍,金鑫瑶,赵宏杰,李越,郑文科..保妇康栓治疗宫颈高危型人乳头瘤病毒感染性疾病有效性和安全性系统评价[J].天津中医药,2018,35(3):195-199,5.基金项目
教育部新世纪优秀人才项目(NCET-13-0936) （NCET-13-0936）
天津市131创新人才培养工程第三层次项目. （）
